Publications by authors named "Tiffany Razabdouski"
Article Synopsis
- New treatment strategies are urgently needed for patients with triple-negative Myelofibrosis (TN-MF), who show poor outcomes and lack mutations in the JAK2 pathway.
- Research reveals that MYC copy number gain and elevated MYC expression are common in TN-MF, driving the disease's development through the activation of S100A9, an inflammation-related protein.
- Targeting the MYC-S100A9 pathway, either through genetic methods or small molecules, effectively improves Myelofibrosis symptoms, presenting a potential new treatment approach for this difficult-to-treat patient group.
Sarcomas are rare and heterogeneous mesenchymal tumors affecting both pediatric and adult populations with more than 70 recognized histologies. Doxorubicin and ifosfamide have been the main course of therapy for treatment of sarcomas; however, the response rate to these therapies is about 10-20% in metastatic setting. Toxicity with the drug combination is high, response rates remain low, and improvement in overall survival, especially in the metastatic disease, remains negligible and new agents are needed.
View Article and Find Full Text PDF